Comparative Pharmacology
Head-to-head clinical analysis: AMMONIA N 13 versus CARDIOLITE.
Peer-Reviewed Evidence
Head-to-head clinical analysis: AMMONIA N 13 versus CARDIOLITE.
AMMONIA N 13 vs CARDIOLITE
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Ammonia N 13 is a radioactive diagnostic agent that is used as a tracer for positron emission tomography (PET) imaging. After intravenous injection, it distributes in the body and is taken up by cells, particularly in the myocardium and brain, via active transport and passive diffusion. Its accumulation reflects regional blood flow and metabolic activity.
Technetium Tc-99m sestamibi is a lipophilic cation that accumulates in myocardial cells via passive diffusion across the sarcolemmal and mitochondrial membranes. Its uptake is proportional to myocardial blood flow and viability, allowing for imaging of myocardial perfusion.
1110-1850 MBq (30-50 mCi) intravenous bolus for PET imaging; single dose per imaging session. No repeated dosing within 24 hours.
CARDIOLITE (Technetium-99m sestamibi) is administered intravenously. For myocardial perfusion imaging, adult dose: 10-40 mCi (370-1480 MBq), administered as a single bolus.
None Documented
None Documented
9–12 minutes (blood) for ammonia; incorporation into glutamine may extend effective half-life for imaging purposes; rapid clearance limits toxicity.
Terminal elimination half-life: 6-8 hours; prolonged in elderly and renal impairment (up to 12-16 hours).
Primary renal excretion; >95% eliminated as unchanged ammonia via glomerular filtration and tubular secretion. Minimal biliary/fecal excretion.
Renal: 85-90% as unchanged drug; fecal: <5%
Category C
Category C
Diagnostic Radiopharmaceutical
Diagnostic Radiopharmaceutical